Atlas Trials

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Clinical trial NCT01674647 · COMPLETED

Trial details

NCT number
NCT01674647
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Atrial Fibrillation
Start date
2012-10-01
Primary completion
2014-01-01
Enrollment
1504

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.